Form PRE 14A Co-Diagnostics, Inc. For: Sep 21

Mon, 21 Sep 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260921/27085967.html

Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation

Mon, 21 Sep 2026 09:00:00 -0400

Roundtable discussion, taking place in New York City, will examine the ongoing Ebola outbreak and technologies needed to strengthen future outbreak response.

Co-Dx will join officials from the U.S. Department of State's Bureau of Global Health Security and Diplomacy and leaders from across the global health research and development community.

Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation

Mon, 21 Sep 2026 09:00:00 -0400

Roundtable discussion, taking place in New York City, will examine the ongoing Ebola outbreak and technologies needed to strengthen future outbreak response.

Co-Dx will join officials from the U.S. Department of State's Bureau of Global Health Security and Diplomacy and leaders from across the global health research and development community.

Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026

Thu, 17 Sep 2026 09:00:00 -0400

SALT LAKE CITY, Sept. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will participate in the upcoming joint WHO/Unitaid/UNAIDS Annual Consultation Meeting. Joseph Featherstone, Executive Vice President of Business Development, will represent Co-Dx at the annual meeting, which will be held at the

Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026

Thu, 17 Sep 2026 09:00:00 -0400

Form 8-K Co-Diagnostics, Inc. For: Sep 16

Wed, 16 Sep 2026 10:30:00 -0400

si-local-file:///var/storage/secattach/20260916/27068844.html

Co-Diagnostics and ReadyGo to test blood-based Ebola detection

Wed, 16 Sep 2026 08:46:01 -0400

Co-Diagnostics, Inc. (NASDAQ: CODX) and ReadyGo Diagnostics Ltd. announced a collaboration to evaluate whether ReadyGo's blood sample-preparation technology can be combined with the Co-Dx PCR platform for point-of-need molecular testing, beginning with Ebola virus detection.

The collaboration pairs ReadyGo's GoCollect® system, which prepares capillary blood samples in the field through integrated sample-conditioning chemistry and plasma separation, with Co-Diagnostics' PCR platform, which is designed for decentralized testing environments. The companies said GoCollect's collection chemistry is also intended to inactivate the virus at the point of collection. Compatibility between the two technologies has not yet been established and is the subject of ongoing

Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola

Wed, 16 Sep 2026 08:45:00 -0400

Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C

Co-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of their collaboration

Combining GoCollect® sample preparation with Co-Dx PCR technology could bring blood-based molecular testing closer to patients

Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola

Wed, 16 Sep 2026 08:45:00 -0400

Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C

Co-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of their collaboration

Combining GoCollect® sample preparation with Co-Dx PCR technology could bring blood-based molecular testing closer to patients

Form 8-K Co-Diagnostics, Inc. For: Sep 16

Wed, 16 Sep 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260916/27067989.html

Co-Diagnostics to Hold Press Conference

Tue, 15 Sep 2026 16:15:00 -0400

Media, analysts and investors are welcome to attend in person or via live webcast, Sept. 16 at 10:30 a.m. ET

SALT LAKE CITY, Sept. 15, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will

Co-Diagnostics to Hold Press Conference

Tue, 15 Sep 2026 16:15:00 -0400

Media, analysts and investors are welcome to attend in person or via live webcast, Sept. 16 at 10:30 a.m. ET

Co-Diagnostics signs material transfer agreement with ReadyGo Diagnostics

Tue, 15 Sep 2026 16:08:40 -0400

Co-Diagnostics, Inc. (NASDAQ: CODX) entered into a material transfer agreement with ReadyGo Diagnostics Ltd in August 2026 to evaluate the potential compatibility of ReadyGo's sample collection and preparation technologies with Co-Diagnostics' Co-Dx PCR platform, according to a company statement.

ReadyGo develops technologies designed to simplify the front end of diagnostic testing, including tools intended to collect biological samples, lyse cells, stabilize nucleic acids, and prepare samples for downstream molecular analysis.

Under the agreement, ReadyGo will provide sampling materials to Co-Diagnostics for feasibility studies, including compatibility testing with Co-Diagnostics' products. The Co-Dx PCR platform is being developed to deliver real-time PCR testing in

Form 8-K Co-Diagnostics, Inc. For: Aug 25

Tue, 15 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260915/27064870.html

Form 3 Co-Diagnostics, Inc. For: Sep 02 Filed by: Bohrer Daniel

Mon, 14 Sep 2026 18:50:00 -0400

si-local-file:///var/storage/secattach/20260914/27059653.html

Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida

Thu, 10 Sep 2026 09:00:00 -0400

Two full laboratory installations completed in Florida; installation and customer training underway in Indiana

State surveillance has recorded 73 locally acquired dengue cases and identifies 14 dengue-positive mosquito pools in Florida this season

SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the completion of two new Vector Smart® mosquito surveillance laboratory installations in

Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida

Thu, 10 Sep 2026 09:00:00 -0400

Two full laboratory installations completed in Florida; installation and customer training underway in Indiana

State surveillance has recorded 73 locally acquired dengue cases and identifies 14 dengue-positive mosquito pools in Florida this season

Co-Diagnostics (CODX) files for 3.4M share offering by selling stockholders

Mon, 24 Aug 2026 16:38:35 -0400

Co-Diagnostics (NASDAQ: CODX) filed for up to 3,404,724 share offering by selling stockholders.

Co-Diagnostics (CODX) files for 3.4M share offering by selling stockholders

Mon, 24 Aug 2026 16:38:35 -0400

Co-Diagnostics (NASDAQ: CODX) filed for up to 3,404,724 share offering by selling stockholders.

Form S-3 Co-Diagnostics, Inc.

Mon, 24 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260824/26968521.html

Form S-3 Co-Diagnostics, Inc.

Mon, 24 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260824/26968521.html

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Tue, 18 Aug 2026 09:30:00 -0400

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT

SALT LAKE CITY, Aug. 18, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Company Chief Commercialization Officer Seth Egan recently participated in the Salt Lake Business Journal's 2026 Medical Devices and Innovation Roundtable event, held on Thursday, August 13 and moderated

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Tue, 18 Aug 2026 09:30:00 -0400

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Tue, 18 Aug 2026 09:30:00 -0400

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Tue, 18 Aug 2026 09:30:00 -0400

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT

StreetInsider.com News Articles

Form PRE 14A Co-Diagnostics, Inc. For: Sep 21

Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation

Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation

Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026

Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026

Form 8-K Co-Diagnostics, Inc. For: Sep 16

Co-Diagnostics and ReadyGo to test blood-based Ebola detection

Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola

Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola

Form 8-K Co-Diagnostics, Inc. For: Sep 16

Co-Diagnostics to Hold Press Conference

Co-Diagnostics to Hold Press Conference

Co-Diagnostics signs material transfer agreement with ReadyGo Diagnostics

Form 8-K Co-Diagnostics, Inc. For: Aug 25

Form 3 Co-Diagnostics, Inc. For: Sep 02 Filed by: Bohrer Daniel

Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida

Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida

Co-Diagnostics (CODX) files for 3.4M share offering by selling stockholders

Co-Diagnostics (CODX) files for 3.4M share offering by selling stockholders

Form S-3 Co-Diagnostics, Inc.

Form S-3 Co-Diagnostics, Inc.

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event